Biography

Shalini Sharp currently serves on the Boards of Directors of Neurocrine Biosciences, Organon & Co and BeiGene. Previously, Ms. Sharp served as Chief Financial Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases, and Chief Financial Officer at Agenus, a clinical-stage immuno-oncology company. Earlier, Ms. Sharp held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs. Ms. Sharp previously served on the boards of Mirati Therapeutics (acquired by Bristol Myers Squibb), Array Biopharma (acquired by Pfizer), Sutro Biopharma, Precision Biosciences, and Agenus.

Ms. Sharp received her AB and an MBA from Harvard University.